Loading clinical trials...

Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge | Clinical Trials | Clareo Health

RECRUITINGPHASE2

Phase IIa Trial in Participants With Asthma to Evaluate Impact of Intranasal ETH47 on Development of Asthma-related Symptoms Following Rhinovirus Challenge

A Phase IIa, Double-blind, Randomized, Placebo-controlled Trial in Participants With Asthma to Evaluate the Impact of Intranasal ETH47 on the Development of Asthma-related Symptoms Following Rhinovirus Challenge

NCT07059767•Ethris GmbH

View on ClinicalTrials.gov

Summary

A Phase IIa trial in participants with asthma to evaluate the impact of intranasal ETH47 on the development of asthma-related symptoms following rhinovirus challenge

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
•2. Participants aged ≥18 and ≤65 years at the time of obtaining informed consent.
•3. Diagnosis of clinical asthma (\>12% reversibility following short acting beta 2 agonist (SABA) treatment or PC20 methacholine challenge of \<8 mg/mL).
•4. Stable (no change in medication or dose) asthma maintenance therapy with inhaled glucocorticosteroids (ICS) or ICS + long acting beta 2 agonist (LABA) for at least 3 months prior to dosing.
•5. Clinically stable with no exacerbations within 3 months prior to dosing.
•6. Sero-negative test result to RV-A16.
•7. Participants must agree to use contraception methods (if applicable).

Exclusion Criteria

•1. Any cold symptom within the last month such as sore throat, sneezing, rhinorrhoea, malaise, nasal obstruction or cough.
•2. Evidence of current allergic rhinitis, including perennial allergic rhinitis, or rhinosinusitis or nasal polyps.
•3. History of or current diagnosis of chronic obstructive pulmonary disease, emphysema, cystic fibrosis or bronchiectasis.
•4. The evidence of any other historic, active or chronic disease following a detailed medical and surgical history which, in the Investigator's judgement, puts the participant at risk due to participation in the trial, may influence the results of the trial, or the participant's ability to participate in the trial. This includes a history of emergency room visits or hospital admissions due to common cold.
•5. Current vaper or smoker, or ex-smoker who stopped within the last 12 months or with a \>5 year pack history; current vapers may be included if willing to stop prior to Baseline.

Locations (1)

Virtus Respiratory Research Ltd and Imperial College Healthcare NHS Trust

London, United Kingdom

Key Dates

Start Date

June 24, 2025

Primary Completion Date

June 1, 2026

Completion Date

June 1, 2026

Last Updated

August 11, 2025

Enrollment

ESTIMATED participants

Conditions

Asthma (Diagnosis)

Interventions

ETH47

DRUG

Placebo

DRUG

Contacts

Dr. Philipp Schreppel

CONTACT

+4989244153042 schreppel@ethris.com

Optimizing a Sensor-Enabled mHealth Intervention for Adolescents With Suboptimal Asthma Control

NCT07301060

Asthma (Diagnosis)

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 11, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions